Open AccessClinical Trials in Pancreatic Cancer: A Long Slog
Author(s) -
Enzler Thomas,
Bates Susan
Publication year - 2017
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0453
Subject(s) - gemcitabine , medicine , pancreatic cancer , paclitaxel , clinical trial , placebo , oncology , randomized controlled trial , cancer , deoxycytidine , chemotherapy , alternative medicine , pathology
Many investigators have turned their efforts toward improving the gemcitabine/nab‐paclitaxel combination by the addition of a third agent. This commentary highlights efforts to date, including the Clinical Trial Results by Ko et al.: A Randomized Double‐Blinded Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastati Pancreatic Cancer: The RAINIER Trial.